m6A‐dependent upregulation of ABCD1 is associated with increased tumorigenesis and poor prognosis in ccRCC although the implication of ABCD1 in chemoresistance is not established.[42] METTL3 upregulation is associated with doxorubicin resistance in breast cancer cells due to increased expression of drug efflux pumps that decrease the therapeutic concentration of the drug inside the cells. The gene discussed is METTL3; the disease is breast cancer.